Skip to Content

Renovist II (diatrizoate) Disease Interactions

There are 3 disease interactions with Renovist II (diatrizoate):

Major

Radiopaque contrast agents (Includes Renovist II) ↔ pheochromocytoma

Severe Potential Hazard, Moderate plausibility. Applies to: Pheochromocytoma

Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium. The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.

Moderate

Diatrizoate (Includes Renovist II) ↔ congestive heart failure

Moderate Potential Hazard, Moderate plausibility. Applies to: Congestive Heart Failure

Due to the transitory increase in the circulatory osmotic load, injections with urographic agents should be used with caution in patients with congestive heart failure. Such patients should be observed for several hours following the procedure to detect delayed hemodynamic disturbances.

Moderate

Intravascular contrast agents (Includes Renovist II) ↔ multiple myeloma

Moderate Potential Hazard, Moderate plausibility. Applies to: Multiple Myeloma

A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma. In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death. Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors. The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules. Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.

Renovist II (diatrizoate) drug interactions

There are 269 drug interactions with Renovist II (diatrizoate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide